TipRanks
Advertisement

JSMD - ETF AI Analysis

Compare

Top Page

JSMD

Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD)

Rating:67Neutral
Price Target:―
JSMD, the Janus Henderson Small/Mid Cap Growth Alpha ETF, earns a solid overall rating largely because several key holdings like Medpace, Exelixis, Qualys, and Halozyme show strong financial performance, positive earnings call sentiment, and good growth prospects. These strengths are partly offset by weaker names such as StepStone Group, which faces negative profitability, high leverage, and valuation concerns, and by some holdings with bearish technical trends or overvaluation risks. The main risk factor is the fund’s exposure to smaller growth companies, where high leverage, rich valuations, and occasional bearish momentum can make returns more volatile.
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered strong gains so far this year, indicating that its strategy has recently been working well for investors.
Leading Holdings Showing Solid Momentum
Several of the top positions, such as Sterling Infrastructure, Landstar System, and Enova International, have posted strong gains, helping drive the fund’s overall results.
Balanced Sector Mix in Growth Areas
The fund spreads its investments across key growth-oriented sectors like health care, technology, and industrials, which helps reduce reliance on any single industry.
Negative Factors
Recent Short-Term Weakness
The ETF has slipped over the past month, showing that its performance can be sensitive to short-term market swings.
Underperforming Top Holdings
Some major positions, including Gen Digital, Piper Sandler, and Medpace Holdings, have shown weak recent performance, which can drag on the fund’s returns.
Heavy U.S. Market Concentration
With almost all assets invested in U.S. companies, the fund offers little geographic diversification and is highly exposed to the U.S. economy.

JSMD vs. SPDR S&P 500 ETF (SPY)

JSMD Summary

JSMD, the Janus Henderson Small/Mid Cap Growth Alpha ETF, focuses on fast-growing smaller and mid-sized U.S. companies instead of the usual large household names. It doesn’t track a set index, but follows a growth theme across many sectors like health care, technology, and industrials. Some of its top holdings include Exelixis in health care and Gen Digital in technology. Investors might consider JSMD if they want growth potential and diversification beyond big blue-chip stocks. However, because it leans on smaller growth companies, its price can be more volatile and may rise or fall more than the overall market.
How much will it cost me?The Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) has an expense ratio of 0.3%, which means you’ll pay $3 per year for every $1,000 invested. This is slightly higher than the average for ETFs because it is actively managed, focusing on selecting small and mid-sized companies with growth potential. Active management typically involves more research and decision-making, which can increase costs.
What would affect this ETF?JSMD's focus on small and mid-cap growth companies in sectors like technology, industrials, and healthcare positions it to benefit from innovation and economic expansion in the U.S. However, it could face challenges from rising interest rates, which may impact growth stocks, and economic slowdowns that disproportionately affect smaller companies. Regulatory changes or sector-specific disruptions could also influence its performance.

JSMD Top 10 Holdings

JSMD leans heavily into U.S. small and mid-cap growth, with health care and tech names steering the ship. Halozyme and Medpace are rising stars, giving the fund a strong health care backbone, while Exelixis adds steady support. On the tech side, Gen Digital has been climbing, but CommVault’s mixed, recently lagging action shows not every software bet is paying off. Financials are a wild card: Enova has been a quiet winner, yet StepStone and Piper Sandler are dragging, creating a push-and-pull dynamic that keeps overall performance lively but uneven.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
CommVault Systems1.98%$20.62M$6.07B-23.66%
65
Neutral
Exelixis1.90%$19.80M$14.41B46.07%
78
Outperform
Ryman1.89%$19.71M$8.29B28.77%
66
Neutral
Gen Digital1.86%$19.40M$16.34B-6.19%
67
Neutral
Medpace Holdings1.78%$18.61M$17.59B26.72%
79
Outperform
Halozyme1.61%$16.84M$13.07B48.42%
73
Outperform
Sterling Infrastructure1.61%$16.82M$15.80B38.92%
71
Outperform
StepStone Group1.59%$16.61M$5.62B-30.85%
45
Neutral
Piper Sandler1.57%$16.35M$5.14B-19.79%
67
Neutral
Qualys1.55%$16.17M$6.34B35.92%
78
Outperform

JSMD Technical Analysis

Technical Analysis Sentiment
Negative
Last Price―
Price Trends
50DMA
94.02
Negative
100DMA
94.56
Negative
200DMA
89.32
Positive
Market Momentum
MACD
-1.02
Negative
RSI
41.31
Neutral
STOCH
64.52
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JSMD, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 91.93, equal to the 50-day MA of 94.02, and equal to the 200-day MA of 89.32, indicating a neutral trend. The MACD of -1.02 indicates Negative momentum. The RSI at 41.31 is Neutral, neither overbought nor oversold. The STOCH value of 64.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSMD.

JSMD Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
――$1.03B0.30%
67
Neutral
――$5.82B0.18%
74
Outperform
――$3.44B0.51%
66
Neutral
――$3.01B0.55%
68
Neutral
――$2.89B0.24%
67
Neutral
――$1.44B0.60%
73
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JSMD
Janus Henderson Small/Mid Cap Growth Alpha ETF
90.68
6.56
7.80%
FELG
Fidelity Enhanced Large Cap Growth ETF
―
―
―
CGMM
Capital Group U.S. Small and Mid Cap ETF
―
―
―
TMSL
T. Rowe Price Small-Mid Cap ETF
―
―
―
JMEE
JPMorgan Market Expansion Enhanced Equity ETF
―
―
―
SMIG
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement